Kaitlyn D’Onofrio

DocwireNews

A new study examined factors associated with non-adherence to endocrine therapy among <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/acceptance-and-commitment-therapy-may-reduce-fear-of-recurrence-in-cancer-survivors/">breast cancer</a> patients.&ldquo;For women with hormone receptor positive <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/breast-cancer-death-rates-continue-to-decline-but-at-a-slower-pace/">breast cancer</a>, long&#8208;term endocrine therapy (ET) can greatly reduce the risk of recurrence, yet adherence is low&#8208; particularly among traditionally underserved populations,&rdquo; the study authors established.The study, which was published in <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/pon.5289">Psycho-Oncology</a>, examined data from the Carolina Breast Cancer Study, which included an oversample of black women and women aged younger than 50 years. Patients filled out a survey related to their endocrine therapy medication adherence, particularly assessing the reasons for non-adherence. Principal factor analysis was used to establish latent factors that indicated non-adherence, and multivariable regression was used to identify which characteristics&mdash;both demographic and clinical&mdash;predictive of each endocrine therapy non-adherence factor.Final analysis included 1,231 women. Of the total cohort, more than half (59%) identified at least one obstacle that kept them from adhering to endocrine therapy. Three latent factors were observed, which the researchers defined as barriers associated with:<ul>
<li>Habit (challenges developing medication&#8208;taking behavior)</li>
<li>Tradeoff (high perceived side effect burden and medication safety concerns)</li>
<li>Resource (challenges related to cost or accessibility)</li>
</ul>Women who were aged 50 years and older were less likely to report habit (adjusted risk ratio [aRR]=0.54; 95% confidence interval [CI], 0.43&ndash;0.69) and resource (aRR=0.66; 95% CI, 0.43&ndash;0.99) barriers, but older age was not correlated with tradeoff barriers. Women who were insured through Medicaid, compared to those with private insurance, were more likely to report tradeoff (aRR=1.53; 95% CI, 1.10&ndash;2.13) or resource (aRR=4.43; 95% CI, 2.49&ndash;6.57) barriers. Black women were more likely to report all three barriers: habit (aRR=1.29; 95% CI, 1.09&ndash;1.53), tradeoff (aRR=1.32; 95% CI, 1.09&ndash;1.60), and resource (aRR=4.43; 95% CI, 2.49&ndash;6.57).&ldquo;Endocrine therapy can offer a big benefit for breast cancer survivors, but many of the strategies we use to help women who are struggling with medication adherence are only designed to address one barrier at a time,&rdquo; said Jennifer Spencer, PhD, of the University of North Carolina at Chapel Hill, lead author of the study, <a href="https://www.eurekalert.org/pub_releases/2020-02/w-cfl021920.php">in a press release</a>. &ldquo;Our study finds that there are at least three distinct kinds of barriers that women might experience when taking endocrine therapy&ndash;suggesting that intervention strategies that can help address multiple barriers at once might be more effective, especially for Black women.&rdquo;The authors summarized, &ldquo;Barriers to ET adherence were described by three distinct factors, and strongly associated with sociodemographic characteristics. Barriers to ET adherence appear inadequately addressed for younger, Black, and publicly&#8208;insured breast cancer survivors. These findings underscore the importance of developing multi&#8208;faceted, patient&#8208;centered interventions that address a diverse range of barriers to ET adherence.&rdquo;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Which Breast Cancer Patients Are Least Likely to Adhere to Endocrine Therapy?

Breast Cancer News

A new study examined factors associated with non-adherence to endocrine therapy among breast cancer patients. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe